Cibus Inc. Announces Partial Exercise of Underwriters' Option
Cibus Inc., a key player in the agricultural chemicals industry, has generated buzz with the announcement that it has partially exercised its option with its underwriters in connection with its recent public offering. This action follows the decision by representatives from Roth Capital Partners and A.G.P./Alliance Global Partners (NYSE: GLP) to acquire an extra 289,953 shares of Cibus's Class A common stock at a price of $4.00 per share.
Details of the Underwriters' Option
This partial exercise falls within a 45-day option that was granted to the underwriters during Cibus's public offering of 3,000,000 shares. The original agreement enabled the underwriters to purchase up to an additional 450,000 shares, providing a financial boost for the company after the public offering, which was conducted according to a filed prospectus supplement with the Securities and Exchange Commission (SEC).
Capital Inflow and Opportunities
The events leading to this partial exercise highlight the underwriters' strong confidence in Cibus's operations and growth potential. Following the public offering, which had been recently filed with the SEC, these additional shares became available shortly after the underwriters communicated their interest to Cibus's management.
Recent Corporate Developments
Cibus Inc., previously known as Calyxt (NASDAQ: CLXT), is based in Delaware, with executive offices located in San Diego. The company is publicly traded on The Nasdaq Stock Market LLC under the ticker symbol NASDAQ: CBUS. Recent updates reveal that Cibus is pushing forward with its efforts in seed trait development and is looking to raise $12 million through a public offering to support corporate initiatives and market growth.
Market Insights and Analyst Predictions
This recent move prompted Canaccord Genuity to adjust its price target for Cibus, changing it to $20 from an earlier estimate of $21. Despite this adjustment, the firm has maintained a Buy rating, reflecting a positive outlook on the stock. Meanwhile, Cibus is making significant progress in launching its first three traits in crop programs, emphasizing the company’s dedication to innovation in the agricultural field.
Leadership Updates at Cibus Inc.
In a notable internal shift, Cibus has reported that CFO Wade King will be taking an indefinite leave of absence for personal reasons. During this time, Carlo Broos, the Senior Vice President of Finance, will step in as interim CFO, ensuring that Cibus's financial strategy remains uninterrupted. Even with these leadership changes, Cibus is well-positioned to continue executing its strategic efforts aimed at market entry and building partnerships within the agriculture sector.
Financial Performance and Considerations
For those monitoring Cibus’s financial condition, it's important to note that the company recently disclosed an increase in R&D expenses along with a net loss compared to the previous fiscal year. However, it maintains a strong cash reserve of $30 million. These financial figures offer insights into the company's strategy and underscore its commitment to growth and innovation, even amid various challenges.
Frequently Asked Questions
What recent announcement did Cibus Inc. make regarding its underwriters' option?
Cibus announced a partial exercise of the underwriters' option, leading to the purchase of an additional 289,953 shares of its Class A common stock.
Who are the underwriters involved in Cibus's public offering?
The underwriters involved are Roth Capital Partners and A.G.P./Alliance Global Partners.
What initiatives is Cibus currently focusing on with its raised funds?
Cibus plans to use the raised funds for seed trait development and general corporate purposes.
What changes occurred in the Cibus leadership team?
CFO Wade King has taken an indefinite leave of absence, and Carlo Broos will serve as interim CFO during this period.
How is Cibus projected to perform in the market based on analyst recommendations?
Analysts maintain a generally positive outlook, with a Buy rating from Canaccord Genuity despite adjustments to price targets, reflecting confidence in Cibus's growth potential.
